56,946 Shares in Prothena Co. plc (NASDAQ:PRTA) Purchased by Seven Eight Capital LP

by · The Cerbat Gem

Seven Eight Capital LP acquired a new position in Prothena Co. plc (NASDAQ:PRTA – Free Report) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 56,946 shares of the biotechnology company’s stock, valued at approximately $2,069,000.

Other institutional investors have also bought and sold shares of the company. Headlands Technologies LLC acquired a new stake in Prothena in the 3rd quarter valued at about $74,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Prothena by 351.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,203 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 4,828 shares during the period. HealthInvest Partners AB acquired a new position in Prothena in the fourth quarter worth approximately $303,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Prothena by 28.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,563 shares of the biotechnology company’s stock worth $348,000 after buying an additional 2,099 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its holdings in Prothena by 3.9% in the third quarter. Oppenheimer & Co. Inc. now owns 7,908 shares of the biotechnology company’s stock worth $382,000 after buying an additional 295 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.

Prothena Trading Down 2.5 %

Shares of NASDAQ:PRTA traded down $0.55 during trading on Friday, hitting $21.13. 250,227 shares of the company were exchanged, compared to its average volume of 429,736. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -6.50 and a beta of 0.24. Prothena Co. plc has a fifty-two week low of $19.52 and a fifty-two week high of $77.13. The firm has a fifty day moving average price of $21.88 and a two-hundred day moving average price of $28.31.

Prothena (NASDAQ:PRTA – Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($0.13). The firm had revenue of $0.05 million during the quarter, compared to the consensus estimate of $3.75 million. Prothena had a negative net margin of 193.17% and a negative return on equity of 30.48%. During the same quarter last year, the firm earned ($0.89) earnings per share. As a group, research analysts predict that Prothena Co. plc will post -4.69 EPS for the current year.

Analyst Ratings Changes

PRTA has been the topic of several analyst reports. StockNews.com downgraded Prothena from a “hold” rating to a “sell” rating in a report on Monday, February 19th. Royal Bank of Canada dropped their price objective on Prothena from $36.00 to $35.00 and set a “sector perform” rating for the company in a research note on Friday, February 16th. JMP Securities dropped their price objective on Prothena from $85.00 to $83.00 and set a “market outperform” rating for the company in a research note on Thursday, May 9th. Oppenheimer lowered their target price on Prothena from $98.00 to $80.00 and set an “outperform” rating for the company in a research note on Tuesday, February 20th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research note on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Prothena currently has an average rating of “Moderate Buy” and an average price target of $67.00.

Get Our Latest Stock Report on PRTA

Prothena Company Profile

(Free Report)

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

See Also

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Co. plc (NASDAQ:PRTA – Free Report).